Complex Size: 900 KDa
Potency: KFDA/In-House 80-125/95-115
Endotoxin Level(EU/Vial): KFDA/In-House <1.0/0.175
Molsture: Less than 3%
Explration: 24months from the date of manufacture
The use of botulinum toxin type A to reduce the volume of muscles such as masseter, temporalis, calf, and deltoid is becoming more popular and promise to have increasingly broader applications.
Meditoxin 100u (Type A) Similarly to Botox, temporarily corrects certain types of medium to deep facial wrinkles by relaxing the muscles into which it was applied. This property also makes it suitable not only for therapeutic cosmetic procedures but also for medical treatment of various conditions among which are blepharospasm, TMJ, stroke recovery and many more.
Resume normal work right away
Just by few tiny injections
Effects visible after one administration, starting from 2 weeks after injection, and peaks around 3~4 weeks.
Painless even when used without aenesthetic
Effects last for 6~12 months
Approved by Health Authorities with over 8 years’ clinical practices.
There is the possibility of reactions at the site of an injection, and effects beyond the injection site, including but not limited to asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. Serious hypersensitivity has been reported as rare.
There is a caution for people with pre-existing neuromuscular disorders, and for those with corneal exposure and ulceration in blepharospasm.
Botulium Toxin Type A is not to be administered at all if a patient has a known allergy to any of the ingredients, or if the patients have neuromuscular junctional disorders or known to have adverse reactions.
To preserve results achieved after a treatment with this Botulinum Toxin Type A injectable, patients need to undergo maintenance injection procedure
Hipretty PDO Thread
Younsofill Dermal Fillers
Cindella + Luthione + VitaminC